+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07372352

Phase II Study of Zeprumetostat, Azacitidine, and Liposomal Mitoxantrone for Relapsed or Refractory Peripheral T-Cell Lymphoma in Adults

Led by The First Affiliated Hospital of Soochow University · Updated on 2026-01-28

26

Participants Needed

1

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment combination for adults with relapsed or refractory peripheral T-cell lymphoma PTCL, an aggressive type of non-Hodgkin lymphoma with limited options after initial therapy. This Phase II study focuses on the effectiveness and safety of combining Zeprumetostat, Azacitidine, and Mitoxantrone Hydrochloride Liposome. The study also explores genetic markers and viral infections that might influence treatment response, addressing a high unmet medical need. Participants will receive up to six 21-day cycles of induction therapy with all three drugs Zeprumetostat taken orally twice daily, Azacitidine via subcutaneous injection on days 1 to 5, and Mitoxantrone Hydrochloride Liposome given intravenously on day 1. Response is checked after three cycles, and only those with tumor shrinkage continue with full six cycles. Those who respond then enter maintenance therapy with Zeprumetostat alone for up to two years, continuing treatment until disease progression, unacceptable side effects, withdrawal, or study completion. Throughout the trial, participants will undergo evaluations including tumor response assessments, monitoring of side effects, and safety checks. Researchers will measure the overall response rate after six cycles, progression-free survival, duration of response, overall survival, and any treatment-related adverse events. The study expects to follow patients for up to 60 months to understand long-term outcomes and safety.

CONDITIONS

Brief Title

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

Research Team

T

Ting Xu, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here